Sensyne Health PLC Board Change (9638E)
24 October 2018 - 5:00PM
UK Regulatory
TIDMSENS
RNS Number : 9638E
Sensyne Health PLC
24 October 2018
Sensyne Health plc
Board Change
Oxford, UK; 24 October 2018: Sensyne Health plc (LSE: SENS), the
British clinical AI technology company, today announces that
Professor Sir John Bell has stepped down as Chairman of the Board
to avoid any potential conflicts of interest that may arise from
his role advising the UK Government on the Life Sciences Industrial
Strategy. In this role, Professor Bell authored the Life Sciences
Strategy Document and has been instrumental in delivering a
programme defined in the report to grow the life sciences sector in
the UK.
Charles Swingland will replace Professor Bell as Chairman on an
interim basis before returning to his Non-Executive Director
position when a search for a permanent Chairman has concluded.
Building on its unique business model and proven acceptance by
both the UK Government and the NHS, Sensyne Health is actively
exploring scaling up its business further including responding to
any government-led initiatives involving NHS datasets.
Commenting on today's announcement, Lord (Paul) Drayson, Chief
Executive Officer of Sensyne Health plc, said: "On behalf of the
Board, I thank John for his significant contribution to this
company and his leadership of the Board through the successful IPO.
Sensyne is committed to transparency and good corporate governance
so we understand his obligation to step away from Sensyne as we
pursue our commitment to improve patient health, medical practices
and NHS healthcare costs and efficiencies through the analysis of
both larger volumes of anonymised UK patient data and additional
healthcare data sets."
Professor Sir John Bell said: "I have thoroughly enjoyed my time
at Sensyne, supporting the business through its initial development
and recent successes. Now is the right time to relinquish my Board
responsibilities to avoid any potential conflicts of interest."
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) +44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive
Officer
Lorimer Headley, Chief Financial Officer
Laura Steward, Head of Marketing
Peel Hunt LLP (Nominated Adviser and
Broker) + 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Consilium Strategic Communications +44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a healthcare technology company that
creates value from accelerating the discovery and development of
new medicines and improving patient care through the analysis of
real-world evidence from large databases of anonymised patient data
in collaboration with NHS Trusts. These anonymised patient data are
ethically sourced in that any analysis of anonymised patient data
(and hence the Company's access to it) must be pre-approved for
each programme on a case-by-case basis by the relevant NHS Trusts.
This is to ensure that the purpose of the anonymisation and the
proposed analysis are subject to appropriate ethical oversight and
information governance, including conformance with NHS principles,
UK data protection law and applicable regulatory guidance. Sensyne
Health is an early signatory to the Department of Health and Social
Care's 'Initial Code of Conduct for data-driven health and care
technology'.
Sensyne Health is listed on the AIM Market of the London Stock
Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAMJBTTMBBTTAP
(END) Dow Jones Newswires
October 24, 2018 02:00 ET (06:00 GMT)
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensyne Health (LSE:SENS)
Historical Stock Chart
From May 2023 to May 2024